Cite this: Genetics and Genomics: Providing new Opportunities for the Translation of Basic Research to Clinical Care for Cystic Fibrosis - Medscape - Feb 01, 2008. Faten Zaibak, Department of ...

In our experience, most couples do not regard preimplantation genetic diagnosis as raising the same ethical dilemmas as prenatal testing at 10–12 weeks, followed by an abortion. Perhaps this is ...

Genetic wellness tests are crucial for early ... or prone you are to risk-factors such as hypertension, cancer, and even ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and progressive genetic disease, the company said on Friday, expanding its dominance in ...

Fair Therapeutics B.V. has completed enrollment of its Phase IIb CHOICES trial, evaluating the novel CFTR triple modulator therapy, Diponecaftor, for adults with ultra-rare cystic fibrosis (CF) ...

I look forward to mentoring graduate students in the genetics lab. Decker ... (2005) Genetic Modifiers of lung disease in cystic fibrosis. New England Journal of Medicine 353(14): 1443:53. Darrah R, ...

Bad memory? Poor sleep habits? These inherited traits may come from your parents. But who's to blame? Here's what the science ...

Israeli startup Identifai develops first maternal blood test to identify risk of 250 genetic diseases as early as 9th week of ...

CF is an inherited progressive disease caused by ... "4DMT reveals positive interim Phase I/II data for cystic fibrosis gene therapy" was originally created and published by Clinical Trials ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

MOMA-313 is under clinical development by Moma Therapeutics and currently in Phase I for Metastatic Prostate Cancer.

MOMA-313 is under development for the treatment of solid tumors including metastatic breast cancer, metastatic pancreatic cancer, metastatic prostate cancer. It acts by targeting DNA polymerase theta.